Cargando…

Assessing the evidence on remdesivir

Detalles Bibliográficos
Autores principales:	Trøseid, Marius, Hites, Maya, Barratt-Due, Andreas, Ader, Florence, Yazdanpanah, Yazdan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760123/ https://www.ncbi.nlm.nih.gov/pubmed/34838222 http://dx.doi.org/10.1016/S1473-3099(21)00695-2

Ejemplares similares

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19
por: Ader, Florence, et al.
Publicado: (2022)

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: author's response
por: Trøseid, Marius, et al.
Publicado: (2022)

Assessing the evidence on remdesivir
por: Núñez, Isaac, et al.
Publicado: (2021)

Remdesivir modifies interferon response in hospitalized COVID-19 patients
por: Murphy, Sarah L., et al.
Publicado: (2022)

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
por: Ader, Florence, et al.
Publicado: (2022)

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
por: Amstutz, Alain, et al.
Publicado: (2023)

Immunocompromised patients have been neglected in COVID-19 trials: a call for action
por: Trøseid, Marius, et al.
Publicado: (2022)

Remdesivir and COVID-19
por: Glaus, Matthew J, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Wang, Lei-Yun, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Dennis, Alicia
Publicado: (2020)

Remdesivir and COVID-19
por: Edwards, Jessie K, et al.
Publicado: (2020)

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group
por: Diallo, Alpha, et al.
Publicado: (2022)

Reduced Cardiac Function by Echocardiography in a Minority of COVID-19 Patients 3 Months after Hospitalization
por: Tangen, Jorun, et al.
Publicado: (2022)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
por: Hentzien, Maxime, et al.
Publicado: (2022)

Strengthening the global effort on COVID-19 research
por: Norton, Alice, et al.
Publicado: (2020)

Remdesivir therapy associated with Bradycardia in SARS‐CoV2
por: Kumar, Sabina, et al.
Publicado: (2021)

Remdesivir-Induced Liver Injury in a COVID-Positive Newborn
por: Kaur, Manjit, et al.
Publicado: (2022)

Reply: Potential risk associated with direct modulation of the gut flora in patients with heart failure
por: Mayerhofer, Cristiane C.K., et al.
Publicado: (2019)

The COVID‐19 Medicine Remdesivir Is Therapeutically Activated by Carboxylesterase‐1, and Excessive Hydrolysis Increases Cytotoxicity
por: Shen, Yue, et al.
Publicado: (2021)

Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection
por: Sanchez-Codez, Maria Isabel, et al.
Publicado: (2021)

COVID-19 Delta variation; more contagious or more pernicious?
por: Yazdanpanah, Fereshteh, et al.
Publicado: (2021)

Case report study of the first five COVID-19 patients treated with remdesivir in France
por: Dubert, Marie, et al.
Publicado: (2020)

Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient
por: Monneret, Guillaume, et al.
Publicado: (2020)

Assessing Evidence Quality for Endovascular Arteriovenous Fistulas
por: Shimamura, Yoshinosuke, et al.
Publicado: (2022)

Management of pharmacovigilance during the COVID‐19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial
por: Mercier, Noémie, et al.
Publicado: (2023)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

Minireview on Novel Anti-infectious Treatment Options and Optimized Drug Regimens for Sepsis
por: Hites, Maya
Publicado: (2021)

Benefit-risk assessment for remdesivir in COVID-19
Publicado: (2020)

Sicily statement on classification and development of evidence-based practice learning assessment tools
por: Tilson, Julie K, et al.
Publicado: (2011)

Les antirétroviraux ont-ils une place dans le traitement du syndrome respiratoire aigu sévère ?
por: Yazdanpanah, Yazdan, et al.
Publicado: (2006)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Remdesivir – Current evidence & perspective in management of COVID-19 infection
por: Bajpai, Jyoti, et al.
Publicado: (2021)

Remdesivir Use in the Real-World Setting: An Overview of Available Evidence
por: Akinosoglou, Karolina, et al.
Publicado: (2023)

Gut microbiota and acute coronary syndromes: ready for use in the emergency room?
por: Trøseid, Marius
Publicado: (2017)

Revisiting the evidence for physical distancing, face masks, and eye protection
por: Conly, John, et al.
Publicado: (2021)

Meta-research studies in surgery: a field that should be encouraged to assess and improve the quality of surgical evidence
por: Lozada-Martinez, Ivan D., et al.
Publicado: (2023)

Nebulised interferon beta-1a for patients with COVID-19
por: Peiffer-Smadja, Nathan, et al.
Publicado: (2021)

HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges?
por: Rockstroh, Jürgen Kurt, et al.
Publicado: (2019)

Remdesivir: Infusion site reaction following extravasation of remdesivir: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o5oh3viq9o2v59rk613e6drptk